LLY

999.72

-0.87%↓

JNJ

228.72

-0.55%↓

ABBV

209.65

-0.64%↓

UNH

392.43

-1.41%↓

AZN

181.63

-2.12%↓

LLY

999.72

-0.87%↓

JNJ

228.72

-0.55%↓

ABBV

209.65

-0.64%↓

UNH

392.43

-1.41%↓

AZN

181.63

-2.12%↓

LLY

999.72

-0.87%↓

JNJ

228.72

-0.55%↓

ABBV

209.65

-0.64%↓

UNH

392.43

-1.41%↓

AZN

181.63

-2.12%↓

LLY

999.72

-0.87%↓

JNJ

228.72

-0.55%↓

ABBV

209.65

-0.64%↓

UNH

392.43

-1.41%↓

AZN

181.63

-2.12%↓

LLY

999.72

-0.87%↓

JNJ

228.72

-0.55%↓

ABBV

209.65

-0.64%↓

UNH

392.43

-1.41%↓

AZN

181.63

-2.12%↓

Strona główna・Stock List・Hutchison China MediTech Ltd ADR

Hutchison China MediTech Ltd ADR

Open

SectorHealthcare

12.48 -0.4

Buy Sell

Overview

Share price change

24h

Current

Min

12.01

Max

12.55

Key metrics
By Trading Economics
Income	227M
Sales	139M
P/E Sector Avg	4.857 51.415
Profit margin	163.843
Employees	1,796
EBITDA	1.3M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+57.85% upside

Market Stats
By TradingEconomics
Market Cap	2.2B
Previous open	12.88
Previous close	12.48

News Sentiment

By Acuity

50%

171 / 346 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

14.24 / 14.78 Support & Resistance

Hutchison China MediTech Ltd ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

14 maj 2026, 22:44 UTC

Acquisitions, Mergers, Takeovers

LVMH to Sell Marc Jacobs Fashion Brand to WHP, G-III Apparel -- 2nd Update

14 maj 2026, 22:27 UTC

Acquisitions, Mergers, Takeovers

LVMH Selling Marc Jacobs Fashion Brand to WHP, G-III Apparel -- Update

14 maj 2026, 22:12 UTC

Earnings

Applied Materials Raises Outlook as Semiconductor Equipment Demand Grows -- 2nd Update

14 maj 2026, 21:52 UTC

Acquisitions, Mergers, Takeovers

LVMH to Sell Marc Jacobs

15 maj 2026, 00:00 UTC

Earnings

Honda's Never Faced a Crisis Like This -- And a Comeback Won't Be Easy -- WSJ

14 maj 2026, 23:57 UTC

Acquisitions, Mergers, Takeovers

Kakao: Stake Sales Aim to Secure Funds for Future Investments

14 maj 2026, 23:56 UTC

Acquisitions, Mergers, Takeovers

Kakao: Share Sale to Lower Kakao Investment's Stake in Dunmau to 4.03%

14 maj 2026, 23:56 UTC

Acquisitions, Mergers, Takeovers

Kakao: Affiliate Kakao Investment to Sell 2.3M Dunamu Shares on June 15

14 maj 2026, 23:56 UTC

Market Talk

Gold Prices Rise on Strong Demand -- Market Talk

14 maj 2026, 23:56 UTC

Acquisitions, Mergers, Takeovers

Kakao to Sell 6.55% Stake in Crypto Exchange Operator Dunamu to Hana Financial for KRW1.003T

14 maj 2026, 23:50 UTC

Market Talk

Global Equities Roundup: Market Talk

14 maj 2026, 23:50 UTC

Market Talk

Nikkei May Rise as AI Enthusiasm Continues -- Market Talk

14 maj 2026, 23:47 UTC

Earnings

JSW Steel: Prolonged Supply-Chain Disruptions Due to Middle East Crisis Pose Risk to Growth >500228.BY

14 maj 2026, 23:47 UTC

Earnings

JSW Steel Results Supported by Higher Steel Prices, One-Off Divestment Gains >500228.BY

14 maj 2026, 23:46 UTC

Earnings

JSW Steel 4Q Net INR163.7B Vs. Net INR21.39B >500228.BY

14 maj 2026, 23:46 UTC

Earnings

JSW Steel 4Q Rev INR511.8B Vs. INR448.19B >500228.BY

14 maj 2026, 23:28 UTC

Market Talk

New Zealand's Economy Faltering Amid Shocks -- Market Talk

14 maj 2026, 23:00 UTC

Market Talk

Australia's One Nation Party Leads In The Polls -- Market Talk

14 maj 2026, 22:46 UTC

Market Talk

Global Equities Roundup: Market Talk

14 maj 2026, 22:46 UTC

Market Talk

Court Decision 'Negative But Balanced' for Coles -- Market Talk

14 maj 2026, 22:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

14 maj 2026, 22:35 UTC

Market Talk

Fed's Warsh Talks Big Game; Will Focus On Credibility First -- Market Talk

14 maj 2026, 22:11 UTC

Acquisitions, Mergers, Takeovers

LVMH Agrees to Sell Marc Jacobs -- WSJ

14 maj 2026, 22:06 UTC

Market Talk

Applied Materials Gets Improved Visibility into Customer Orders -- Market Talk

14 maj 2026, 22:04 UTC

Earnings

Thai Beverage Results Supported by Higher Contributions From Spritis Business >Y92.SG

14 maj 2026, 22:04 UTC

Earnings

Thai Beverage 2Q Net THB7.37B Vs. Net THB6.74B >Y92.SG

14 maj 2026, 22:04 UTC

Earnings

Thai Beverage 2Q Rev THB86.52B Vs. THB85.35B >Y92.SG

14 maj 2026, 22:00 UTC

Earnings

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

14 maj 2026, 21:55 UTC

Earnings

Nu Holdings 1Q EPS 18c >NU

14 maj 2026, 21:55 UTC

Earnings

Nu Holdings 1Q Rev $4.97B >NU

Peer Comparison

Price change

Hutchison China MediTech Ltd ADR Forecast

Price Target

By TipRanks

57.85% upside

12 Months Forecast

Average 20 USD 57.85%

High 20 USD

Low 20 USD

Based on 1 Wall Street analysts offering 12 month price targets forHutchison China MediTech Ltd ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

1 ratings

Buy

Hold

Sell

Based on 1 analysts giving stock ratings to Hutchison China MediTech Ltd ADR - Dist in the past 3 months.

Technical Score

By Trading Central

14.24 / 14.78Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

171 / 346 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.